Atika Capital Management’s Edwards Lifesciences EW Stock Holding History

Atika Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29,000	Closed	-$2.4M	–	82
2022 Q3	$2.4M	Buy	+29,000	New	+$2.79M	0.2%	80
2020 Q1	–	Sell	-42,000	Closed	-$3.27M	–	91
2019 Q4	$3.27M	Buy	42,000 +18,000	+75%	+$1.41M	0.63%	57
2019 Q3	$1.76M	Buy	+24,000	New	+$1.69M	0.37%	64
2016 Q4	–	Sell	-102,000	Closed	-$4.1M	–	64
2016 Q3	$4.1M	Buy	+102,000	New	+$3.84M	1.67%	19
2016 Q2	–	Sell	-42,000	Closed	-$1.23M	–	65
2016 Q1	$1.23M	Buy	+42,000	New	+$1.16M	0.75%	41
2015 Q2	–	Sell	-138,000	Closed	-$3.28M	–	71
2015 Q1	$3.28M	Buy	+138,000	New	+$3.1M	2.19%	14

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atika Capital Management's EW Position: Q4 2022 in Review

Atika Capital Management sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 29,000 shares — an estimated $2.4M sold.

Atika Capital Management first reported a position in EW in Q1 2015 and held it in 6 quarters. The position peaked at $4.1M in Q3 2016. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

Atika Capital Management reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
Atika Capital Management sold 29,000 Edwards Lifesciences shares in Q4 2022, an estimated $2.4M.
Atika Capital Management first reported a position in Edwards Lifesciences in Q1 2015 and held it in 6 quarters.
Atika Capital Management's Edwards Lifesciences position peaked at $4.1M in Q3 2016.
1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on Atika Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.